GLENMARK

Glenmark Pharmaceuticals Limited Gets USFDA Nod for OTC Nasal Spray • 🇺🇸 Regulatory Approval: USFDA clears Fluticasone Propionate Nasal Spray (OTC) • 💊 Market Opportunity: Targets large US allergy market (~$384M sales benchmark) • 📦 Product Launch: To be launched in April 2026 in the US • 🔬 Bioequivalence: Approved as equivalent to Flonase (reference drug) • 🌍 US Expansion: Strengthens OTC portfolio & presence in North America 🟢 Impact: Positive USFDA approval boosts product pipeline, enhances US revenue potential, and supports growth in OTC segment.